Nectar Lifesciences Balance Sheet Health
Financial Health criteria checks 5/6
Nectar Lifesciences has a total shareholder equity of ₹7.2B and total debt of ₹4.6B, which brings its debt-to-equity ratio to 64%. Its total assets and total liabilities are ₹18.1B and ₹11.0B respectively.
Key information
64.01%
Debt to equity ratio
₹4.59b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹64.60m |
| Equity | ₹7.17b |
| Total liabilities | ₹10.98b |
| Total assets | ₹18.15b |
Recent financial health updates
Nectar Lifesciences (NSE:NECLIFE) Seems To Use Debt Quite Sensibly
Dec 15
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Recent updates
Little Excitement Around Nectar Lifesciences Limited's (NSE:NECLIFE) Revenues As Shares Take 30% Pounding
Jul 10More Unpleasant Surprises Could Be In Store For Nectar Lifesciences Limited's (NSE:NECLIFE) Shares After Tumbling 27%
Mar 14Nectar Lifesciences Limited's (NSE:NECLIFE) Revenues Are Not Doing Enough For Some Investors
Jan 28Nectar Lifesciences (NSE:NECLIFE) Seems To Use Debt Quite Sensibly
Dec 15Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive
Oct 11Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth
Aug 22Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Feb 19Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?
Feb 25Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Zooming in on NSE:NECLIFE's 0.3% Dividend Yield
Nov 02Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Sep 07
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
Aug 09The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Aug 09What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E
Jul 13Financial Position Analysis
Short Term Liabilities: NECLIFE's short term assets (₹15.9B) exceed its short term liabilities (₹7.1B).
Long Term Liabilities: NECLIFE's short term assets (₹15.9B) exceed its long term liabilities (₹3.9B).
Debt to Equity History and Analysis
Debt Level: NECLIFE's net debt to equity ratio (63.1%) is considered high.
Reducing Debt: NECLIFE's debt to equity ratio has reduced from 80.7% to 64% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable NECLIFE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: NECLIFE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 3.8% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/12 12:26 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nectar Lifesciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naveed MD. | FirstCall Research |